Page 48 - மருந்துகள் ஒன்றுபட்டது மாநிலங்களில் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hikma launches generic Advair Diskus® following FDA approval News provided by Share this article Share this article LONDON, Dec. 17, 2020 /PRNewswire/  Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKline s Advair Diskus ®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US. Hikma worked with Vectura Group, a UK based provider of innovative inhaler drug delivery solutions, to develop the proprietary dry powder inhaler and formulation technology. According to IQVIA, US sales of Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg/50mcg and 250mcg/50mcg, were approximately $2 billion in the 12 months ending September 2020.

United arab emiratesUnited statesUnited kingdomCity ofSteve weissCharles armitstead camilla cunninghamGlaxosmithkline advair diskusSusan ringdalSiggi olafssonDavid belianAdvair diskusVectura groupGlobal affairsWard columbus incHikma pharmaceuticals united states incUs communications